Introduction to Severe Combined Immunodeficiencies (SCID) and Newborn Screening for SCID
Click CC to turn on closed captioning.
Once identified, newborns with SCID can receive life-sustaining therapy. Delays in identification of affected infants rapidly reduce the success of such treatments. In Part 1 of this 2-part presentation, Dr. Abraham discusses the diagnostic path, use of appropriate laboratory tests and test interpretation tools, and potential treatments for this deadly condition. In Part 2, Dr. Abraham discusses the appropriate use of tier 1, 2, and 3 follow-up testing for abnormal newborn screening for SCID/T cell lymphopenia. Due to the complexity of this information, both recordings are now available.
- Roshini Abraham, PhD
- Associate Professor of Laboratory Medicine/Pathology and Medicine at Mayo Clinic
- Consultant in the Division of Clinical Biochemistry and Immunology at Mayo Clinic in Rochester, Minnesota
- Director of the Cellular and Molecular Immunology Laboratory within the Department of Laboratory Medicine and Pathology
- Director of the Jeffrey Modell Foundation for Primary Immunodeficiencies Diagnostic and Research Center at the Mayo Clinic
The SCID Series
- Hot Topic: Introduction to Severe Combined Immunodeficiencies (SCID) and Newborn Screening for SCID, Part 1
- Hot Topic: Introduction to Severe Combined Immunodeficiencies (SCID) and Newborn Screening for SCID, Part 2
- TREC/87959 T-Cell Receptor Excision Circles (TREC) Analysis for Immune Reconstitution
- CD4RT/89504 CD4 T-Cell Recent Thymic Emigrants (RTE)
- TBBS/9336 T- and B-Cell Quantitation by Flow Cytometry
- LPMGF/60591 Lymphocyte Proliferation to Mitogens, Blood
- TCP/89319 T-Cell Subsets, Naive, Memory and Activated
Forward to a Colleague
Share this presentation with:
- General Practitioners
If you have questions, e-mail .